# US 2025/0059301 A1 · Fusion Protein Construct

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059301 A1
- Document ID: US20250059301A1
- Status: Published application
- Kind: A1
- Application number: 18/805,059
- Filed: 2024-08-14
- Published: 2025-02-20
- Earliest claimed: 2016-06-06
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Milan Mrksich; Justin A. Modica
- Web page: https://patentgrep.com/patent/US20250059301A1

## CPC

- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/32: against translation products of oncogenes
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C12Y 301/01074: Cutinase (3.1.1.74)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- C12Y 201/01037: DNA (cytosine-5-)-methyltransferase (2.1.1.37)
- C12Y 301/21002: Deoxyribonuclease IV (phage-T(4)-induced)(3.1.21.2)
- C12Y 302/01021: Beta-glucosidase (3.2.1.21)
- C12Y 304/11018: Methionyl aminopeptidase (3.4.11.18)
- C12Y 304/24024: Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
- C12Y 305/02006: Beta-lactamase (3.5.2.6)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the linker includes a first and second functional groups specific for irreversibly inhibiting the first and second fusion protein reactive enzymes. The disclosure further provides a method including (a) contacting a first fusion protein including an affinity reagent and a reactive enzyme with a linker including a functional group specific for irreversibly inhibiting the first fusion protein reactive enzyme thereby coupling the first fusion protein and the linker, and (b) contacting a second fusion protein including an affinity reagent and a reactive enzyme with the linker, the linker including a functional group specific for irreversibly inhibiting the second fusion protein reactive enzyme thereby coupling the second fusion protein and the linker.

## Claims

### Claim at position 1

1-171. (canceled)

### Claim 172

A construct comprising
a first fusion protein, a second fusion protein, and a linker,
wherein
the first fusion protein comprises a first reactive enzyme and the second fusion protein comprises a second reactive enzyme; and
the linker comprises a first functional group specific for irreversibly inhibiting the first reactive enzyme at a first terminus, and a second functional group specific for irreversibly inhibiting the second reactive enzyme at a second terminus, wherein the first functional group specific for irreversibly inhibiting the first reactive enzyme is coupled to the first reactive enzyme and the second functional group specific for irreversibly inhibiting the second reactive enzyme is coupled to the second reactive enzyme, such that the first fusion protein and second fusion protein are linked in the form of the construct, and
wherein the first reactive enzyme comprises cutinase and the second reactive enzyme comprises HaloTag or SnapTag.

### Claim 173 (depends on 172)

The construct of claim 172, wherein the first fusion protein further comprises a first affinity reagent and the second fusion protein further comprises a second affinity reagent.

### Claim 174 (depends on 173)

The construct of claim 173, wherein the first fusion protein affinity reagent and second fusion protein affinity reagent are different.

### Claim 175 (depends on 173)

The construct of claim 173, wherein the first and second affinity reagents are independently selected from the group consisting of antibody or fragment thereof, small molecule, monobody, protein, and combinations thereof.

### Claim 176 (depends on 175)

The construct of claim 175, wherein the first affinity reagent comprises an antibody or fragment thereof and the antibody or fragment thereof is selected from the group consisting of a light chain variable domain (VL), a light chain constant domain (CL), a heavy chain variable domain (VH), a heavy chain constant domain (CH1), and a combination thereof.

### Claim 177 (depends on 175)

The construct of claim 175, wherein the first affinity reagent comprises an antibody or fragment thereof and the antibody or fragment thereof is selected from the group consisting of adalimumab, alemtuzumab, arcitumomab, cetuximab, trastuzumab, imciromab, capromab, infliximab, abciximab, rituximab, basiliximab, palivizumab, nofetumomab, omalizumab, daclizumab, ibritumomab tiuxetan, muromonab, edrecolomab gemtuzumab ozogamicin, golimumab, certolizumab, eculizumab, ustekinumab, panitumumab, tositumomab, bevacizumab, raxibacumab, tocilizumab, brentuximab, ofatumumab, belimumab, ramucirumab, vedolizumab, obinutuzumab, pembrolizumab, ranibizumab, pertuzumab, denosumab, catumaxomab, golimumab, siltuximab, natalizumab, panitumumab, and denosumab.

### Claim 178 (depends on 175)

The construct of claim 175, wherein the small molecule is a drug.

### Claim 179 (depends on 178)

The construct of claim 178, wherein the small molecule is selected from the group consisting of aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, aminoglutethimide, L-asparaginase, amifostine, amrubicin, amsacrine, anastrozole, anzmet, aranesp, arglabin, arsenic trioxide, aromasin, 5-azacytidine, azathioprine, BCG or tice-BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulphate, broxuridine, bortezomib, bleomycin, busulfan, calcitonin, campath, capecitabine, carboplatin, carmustine, casodex, cefesone, celmoleukin, cerubidin, chlorambucil, cisplatin, colaspase, cladribin, clodronic acid, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunoxome, decadron, decadron phosphate, delestrogen, denileukin diftitox, depomedrol, deslorelin, dexrazoxane, daunorubicin, diethylstilbestrol, 2′,2′-difluorodeoxycytidine, diflucan, docetaxel, doxifluridine, doxorubicin, dronabinol, DW-166HC, eligard, elitek, ellence, emend, epirubicin, epoetin-alfa, epogen, eptaplatin, ergamisol, estrace, estradiol, estramustine sodium phosphate, ethinylestradiol, ethyol, etidronic acid, etopophos, etoposide, fadrozole, farstone, filgrastim, finasteride, fligrastim, floxuridine, fluconazole, fludarabin, fludarabin phosphate, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, 5-fluorouracil (5-FU), fluoxymesterone, flutamide, hexamethylmelamine, formestane, fosteabine, fotemustine, fulvestrant, gammagard, gemcitabine, gemtuzumab, gleevec, gliadel, goserelin, granisetron hydrochloride, histrelin, hycamtin, hydrocortone, erythro-hydroxynonyladenine, hydroxyurea, hydroxyprogesterone caproate, ibritumomab tiuxetan, idarubicin, ifosfamide, interferon-alpha, interferon-alpha-2, interferon-alpha-2α, interferon-alpha-2β, interferon-alpha-n1, interferon-alpha-n3, interferon-beta, interferon-gamma-1α, interleukin-2, intron A, iressa, irinotecan, kytril, lentinan sulphate, letrozole, leucovorin, leuprolide, leuprolide acetate, levamisole, levofolic acid calcium salt, levothroid, levoxyl, lomustine, lonidamine, marinol, mechlorethamine, mecobalamin, medroxyprogesterone acetate, megestrol acetate, melphalan, menest, 6-mercaptopurine, mesna, methotrexate, metvix, miltefosine, minocycline, mitomycin C, mitotane, mitoxantrone, modrenal, myocet, nedaplatin, neulasta, neumega, neupogen, nilutamide, nolvadex, NSC-631570, OCT-43, octreotide, ondansetron hydrochloride, orapred, oxaliplatin, paclitaxel, pediapred, pegaspargase, pegasys, pentostatin, N-phosphonoacetyl L-aspartate (PALA), picibanil, pilocarpine hydrochloride, pirarubicin, plicamycin, porfimer sodium, prednimustine, prednisolone, prednisone, premarin, procarbazine, procrit, raltitrexed, rebif, rhenium-186 etidronate, rituximab, roferon-A, romurtide, salagen, sandostatin, sargramostim, semustine, sizofiran, sobuzoxane, solu-medrol, streptozocin, strontium-89 chloride, Synthroid, tamoxifen, tamsulosin, tasonermin, tastolactone, taxoter, teceleukin, temozolomide, teniposide, testosterone propionate, testred, thioguanine, thiotepa, thyrotropin, tiludronic acid, topotecan, toremifen, tositumomab, tastuzumab, teosulfan, tretinoin, trexall, trimethylmelamine, trimetrexate, triptorelin acetate, triptorelin pamoate, UFT, uridine, valrubicin, vesnarinone, vinblastine, vincristine, vindesine, vinorelbine, virulizin, zinecard, zinostatin-stimalamer, zofran; ABI-007, acolbifen, actimmune, affinitak, aminopterin, arzoxifen, asoprisnil, atamestane, atrasentan, avastin, BAY 43-9006 (sorafenib), CCI-779, CDC-501, celebrex, cetuximab, crisnatol, cyproterone acetate, decitabine, DN-101, doxorubicin-MTC, dSLIM, dutasteride, edotecarin, eflornithine, exatecan, fenretinide, histamine dihydrochloride, histrelin hydrogel implant, holmium-166 DOTMP, ibandronic acid, interferon-gamma, intron-PEG, ixabepilone, keyhole limpet hemocyanine, L-651582, lanreotide, lasofoxifen, libra, lonafarnib, miproxifen, minodronate, MS-209, liposomal MTP-PE, MX-6, nafarelin, nemorubicin, neovastat, nolatrexed, oblimersen, onko-TCS, osidem, paclitaxel polyglutamate, pamidronate disodium, PN-401, QS-21, quazepam, R-1549, raloxifen, ranpirnas, 13-cis-retic acid, satraplatin, seocalcitol, T-138067, tarceva, taxoprexin, thymosin-alpha-1, tiazofurin, tipifarnib, tirapazamine, TLK-286, toremifen, transMID-107R, valspodar, vapreotide, vatalanib, verteporfin, vinflunin, Z-100, zoledronic acid and combinations of the foregoing.

### Claim 180 (depends on 175)

The construct of claim 175, wherein the affinity reagent is a protein comprising at least one unnatural amino acid, a protein in phage, or a therapeutic protein.

### Claim 181 (depends on 175)

The construct of claim 175, wherein the affinity reagent is selected from the group consisting of designed ankyrin repeat proteins (DARPins), HEL4 Vh domains (Predator), Z-domain of staphylococcal protein A (Affibody), archeal “7 kDa DNA binder” protein family (Affitin), carbohydrate-binding module (CBD domain), cystine-knot miniprotein (knottin), fibronectin type III domain (monobody, Adnectin), γ-B-crystallin (Affilin), cystatins (Affimers), triple helix coiled coil domains (Alphabodies), lipocalin domains (Anticalins), A domains of various membrane receptors (Avimers), SH3 domains of Fyn (Fynomers), Kunitz domain peptides, and combinations thereof.

### Claim 182 (depends on 172)

The construct of claim 172, wherein the linker is a polyoxazoline, polyacrylomorpholine, polyvinylpyrrolidone, polyphosphazene, polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, poly(1-hydroxymethylethylene hydroxymethyl formal) (“PHF”), a polyhydroxyalkylacrylate, 2-methyacryloyloxy-2′-ethyltrimethylammonium phosphate (“MPC”), or a structure selected from:
wherein:
m is 0-10;
n is 1-100;
each p independently is 0, 1, 2, 3, or 4;
q is 0, 1, or 2;
r is 1 or 2;
E is NH or CHR10;
G is O, CH2, CHOH, CHNH2, CHCOOH, or CHSO3H;
R10 is OH, NH2, or COOH;
each R11 independently is H, OH, NH2, or COOH.

### Claim 183

A method comprising
(a) contacting a first fusion protein comprising a first reactive enzyme comprising cutinase with a linker comprising a functional group specific for irreversibly inhibiting the first reactive enzyme at a first terminus thereby coupling the first fusion protein and the linker at the first terminus, and
(b) contacting a second fusion protein comprising a second reactive enzyme comprising HaloTag or SnapTag with a second terminus of the linker, the second terminus of the linker comprising a functional group specific for irreversibly inhibiting the second reactive enzyme thereby coupling the second fusion protein and the linker at the second terminus.

### Claim 184 (depends on 183)

The method of claim 183, wherein steps (a) and (b) are performed sequentially.

### Claim 185 (depends on 183)

The method of claim 183, wherein steps (a) and (b) are preformed contemporaneously.

### Claim 186 (depends on 183)

The method of claim 183, wherein the first fusion protein further comprises a first affinity reagent and the second fusion protein further comprises a second affinity reagent.

### Claim 187 (depends on 186)

The method of claim 186, wherein the first and second affinity reagents are independently selected from the group consisting of antibody or fragment thereof, small molecule, monobody, protein, and combinations thereof.

### Claim 188 (depends on 186)

The method of claim 186, wherein the first and/or second affinity reagent is selected from the group consisting of designed ankyrin repeat proteins (DARPins), HEL4 Vh domains (Predator), Z-domain of staphylococcal protein A (Affibody), archeal “7 kDa DNA binder” protein family (Affitin), carbohydrate-binding module (CBD domain), cystine-knot miniprotein (knottin), fibronectin type III domain (monobody, Adnectin), γ-B-crystallin (Affilin), cystatins (Affimers), triple helix coiled coil domains (Alphabodies), lipocalin domains (Anticalins), A domains of various membrane receptors (Avimers), SH3 domains of Fyn (Fynomers), Kunitz domain peptides, and combinations thereof.

### Claim 189 (depends on 183)

The method of claim 183, wherein the linker is a of polyoxazoline, polyacrylomorpholine, polyvinylpyrrolidone, polyphosphazene, polyethylene-co-maleic acid anhydride, polystyrene-co-maleic acid anhydride, poly(1-hydroxymethylethylene hydroxymethyl formal) (“PHF”), a polyhydroxyalkylacrylate, 2-methyacryloyloxy-2′-ethyltrimethylammonium phosphate (“MPC”), or a structure selected from:
wherein:
m is 0-10;
n is 1-100;
each p independently is 0, 1, 2, 3, or 4;
q is 0, 1, or 2;
r is 1 or 2;
E is NH or CHR10;
G is O, CH2, CHOH, CHNH2, CHCOOH, or CHSO3H;
R10 is OH, NH2, or COOH;
each R11 independently is H, OH, NH2, or COOH.

### Claim 190 (depends on 172)

A method comprising administering the construct of claim 172 to a patient in need thereof.

### Claim 191 (depends on 190)

The method of claim 190, wherein the patient suffers from breast cancer, inhalational anthrax, rheumatoid arthritis, systemic juvenile idiopathic arthritis, Hodgkin lymphoma, systemic anaplastic large cell lymphoma, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, multiple sclerosis, systemic lupus erythematosus, gastric or gastro-esophageal junction adenocarcinoma, metastatic non-small-cell lung carcinoma, ulcerative colitis, Crohn's disease, follicular lymphoma, melanoma, macular degeneration, osteoporosis, treatment-induced bone loss, metastases to bone, giant cell tumor of bone, malignant ascites, psoriatic arthritis, ankylosing spondylitis, metastatic renal cell cancer, prostate cancer, ovarian cancer, colorectal cancer, multiple myeloma, and Castleman's disease.
